Optiscan has been featured in a Stockhead article examining how ASX-listed healthcare companies are working to reduce post-surgical complications and improve patient outcomes, with a particular focus on technologies designed to minimise repeat procedures and support precision surgery.

The article highlights Optiscan’s miniaturised confocal endomicroscopic imaging technology, which is designed to provide surgeons and pathologists with real-time microscopic imaging during surgery to help ensure tumours are removed with clear margins the first time. By enabling live collaboration during procedures, the technology aims to reduce the need for follow-up surgeries caused by incomplete tumour removal.

Stockhead notes that one third of breast lumpectomy patients can require additional surgery when tumours are not fully removed, with Optiscan positioning its technology as a precision tool to support more accurate surgical decision-making.

The article also references Optiscan’s advancing clinical studies, including its breast cancer surgery trial at the Royal Melbourne Hospital and head and neck cancer study at St John of God Murdoch Hospital in Perth, where the technology is being used to provide live tissue biopsy insights during procedures.

In addition, the report highlights Optiscan’s collaboration with Mayo Clinic in the United States to integrate real-time imaging into robotic surgery platforms, as well as the broad applicability of the company’s technology across multiple cancer types and tissue applications.

“Our probe can scan a 3D cavity in real time to obtain imaging at the single cell microscopic level, so the pathologist gets all the information they need to make a decision on the spot,” said Optiscan CEO and Managing Director Dr Camile Farah.

Stockhead – Read the full article here